Technology in Type 1 Diabetes Gets Patients Closer to Targets
SHILADITYA last edited by
The odds of a person with type 1 diabetes achieving target A1c levels and avoiding severe hypoglycemia increase with greater degrees of automation in the technology they're using, new real-world data show. Most notably, the likelihood of experiencing a severe hypoglycemic episode in the prior year was more than double for those taking multiple daily injections (MDI) of insulin without use of a continuous glucose monitor (CGM) compared with those using hybrid closed-loop automated insulin delivery, also known as artificial pancreas systems.
DHITISHREE last edited by
@shiladitya Observations from the T1D Exchange patient registry support findings of clinical trials showing glycemic benefit with hybrid-closed loop [artificial pancreas] use.